Shield Therapeutics shares fall after negative clinical study
A Tyneside pharmaceutical company has seen its shares fall in value after a negative clinical study meant it had to return most of its 2019 income to a commercial partner.
Shield Therapeutics revealed in a trading update that a clinical study on its Ferracru product – which treats iron deficiency – had “not met its primary endpoint.”
Shield has a licencing agreement with Dutch firm Norgine to…
Discover more from USNewsRank
Subscribe to get the latest posts sent to your email.